北京大学学报(医学版) ›› 2023, Vol. 55 ›› Issue (2): 308-314. doi: 10.19723/j.issn.1671-167X.2023.02.015
Lin NONG*(),Wei WANG,Li LIANG,Dong LI,Xin LI,Ting LI
摘要:
目的: 分析母细胞性浆样树突细胞肿瘤(blastic plasmacytoid dendritic cell neoplasm,BPDCN)的临床病理学特征。方法: 收集2013年1月至2022年3月北京大学第一医院确诊的BPDCN患者的病历资料共13例,回顾性分析患者的临床表现、组织病理学特征、免疫表型及其预后。结果: 13例患者男性11例,女性2例,中位年龄62岁(5~78岁)。13例中单器官受累5例,均为皮肤受累;多器官受累8例(皮肤/脑/乳腺+骨髓受累3例,皮肤+骨髓+淋巴结受累3例,皮肤+骨髓+淋巴结+脾受累2例)。组织病理学分析以中等至大型幼稚母细胞一致性增生浸润为特征,浸润皮肤真皮全层,骨髓病变以弥漫性浸润为主,淋巴结受累时淋巴结结构完全破坏,脾累及者主要侵犯脾红髓。免疫组织化学染色显示,13例均不同程度阳性表达CD4、CD56、CD123(13/13),9例均表达TCL1(9/9);部分表达CD68(KP1)(8/13)、TdT(7/12),CD117(2/6),显示高Ki-67增殖指数(40%~80%);不表达CD20、CD3、CD34、MPO、CD30;EBER原位杂交阴性(0/9)。明确诊断后6例接受化疗,其中1例辅以放疗,2例接受后续骨髓移植;另有2例仅维持治疗;随访中位时间14个月(6~36个月),5例死于疾病进展(6~18个月),3例存活(7~36个月),5例失访。结论: BPDCN是罕见的恶性淋巴造血系肿瘤类型,侵袭性强,临床预后较差。诊断需结合临床特征、组织病理学、免疫组织化学表型,并注意与其他母细胞形态或CD4+CD56+淋巴造血系肿瘤相鉴别。
中图分类号:
1 |
Herling M , Jones D . CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells[J]. Am J Clin Pathol, 2007, 127 (5): 687- 700.
doi: 10.1309/FY6PK436NBK0RYD4 |
2 |
Brody JP , Allen S , Schulman P , et al. Acute agranular CD4-positive natural killer cell leukemia. Comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents[J]. Cancer, 1995, 75 (10): 2474- 2483.
doi: 10.1002/1097-0142(19950515)75:10<2474::AID-CNCR2820751013>3.0.CO;2-Y |
3 | Facchetti F, Jones D, Petrella T. Blastic plasmacytoid dendritic cell neoplasm [M]//Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2008: 145-147. |
4 | Facchetti F, Petrella T, Pileri SA. Blastic plasmacytoid dendritic cell neoplasm [M]// Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2017: 174-177. |
5 |
Khoury JD , Solary E , Abla O , et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Myeloid and histiocytic/dendritic neoplasms[J]. Leukemia, 2022, 36 (7): 1703- 1719.
doi: 10.1038/s41375-022-01613-1 |
6 |
Liao C , Hu NX , Song H , et al. Pediatric blastic plasmacytoid dendritic cell neoplasm: Report of four cases and review of literature[J]. Int J Hematol, 2021, 113 (5): 751- 759.
doi: 10.1007/s12185-020-03070-x |
7 |
Garnache-Ottou F , Vidal C , Biichlé S , et al. How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients[J]. Blood Adv, 2019, 3 (24): 4238- 4251.
doi: 10.1182/bloodadvances.2019000647 |
8 |
Sweet K . Blastic plasmacytoid dendritic cell neoplasm: Diagnosis, manifestations, and treatment[J]. Curr Opin Hematol, 2020, 27 (2): 103- 107.
doi: 10.1097/MOH.0000000000000569 |
9 | Adnan A, Powell PR, Staples CJ, et al. Blastic plasmacytoid dendritic cell neoplasm: A case series and review [J]. Am J Dermatopathol, 2021(2021-05-11)[2022-11-01]. https://journals.lww.com/amjdermatopathology/Abstract/9000/Blastic_Plasmacytoid_Dendritic_Cell_Neoplasm__A.97747.aspx. |
10 |
Julia F , Petrella T , Beylot-Barry M , et al. Blastic plasmacytoid dendritic cell neoplasm: Clinical features in 90 patients[J]. Br J Dermatol, 2013, 169 (3): 579- 586.
doi: 10.1111/bjd.12412 |
11 |
Taylor J , Haddadin M , Upadhyay VA , et al. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark[J]. Blood, 2019, 134 (8): 678- 687.
doi: 10.1182/blood.2019001144 |
12 |
Brunetti L , Di Battista V , Venanzi A , et al. Blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia: A shared clonal origin[J]. Leukemia, 2017, 31 (5): 1238- 1240.
doi: 10.1038/leu.2017.38 |
13 |
Pagano L , Valentini CG , Grammatico S , et al. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches[J]. Br J Haematol, 2016, 174 (2): 188- 202.
doi: 10.1111/bjh.14146 |
14 |
Jen EY , Gao X , Li L , et al. FDA approval summary: Tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm[J]. Clin Cancer Res, 2020, 26 (3): 532- 536.
doi: 10.1158/1078-0432.CCR-19-2329 |
15 |
Pemmaraju N , Lane AA , Sweet KL , et al. Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm[J]. N Engl J Med, 2019, 380 (17): 1628- 1637.
doi: 10.1056/NEJMoa1815105 |
[1] | 刘媛,原婉琼,李婷,王平章,吕平,吴利新,阮国瑞,韩文玲,莫晓宁. 敲减CMTM3增加急性B淋巴细胞白血病细胞对伊马替尼敏感性[J]. 北京大学学报(医学版), 2022, 54(6): 1238-1243. |
[2] | 曹乐清,周婧睿,陈育红,陈欢,韩伟,陈瑶,张圆圆,闫晨华,程翼飞,莫晓冬,付海霞,韩婷婷,吕萌,孔军,孙于谦,王昱,许兰平,张晓辉,黄晓军. 异基因造血干细胞移植后晚发重症肺炎患者治疗与预后转归的关系[J]. 北京大学学报(医学版), 2022, 54(5): 1013-1020. |
[3] | 刘京,陆爱东,左英熹,吴珺,黄志卓,贾月萍,丁明明,张乐萍,秦炯. 儿童急性淋巴细胞白血病合并癫痫发作75例临床特征和预后分析[J]. 北京大学学报(医学版), 2022, 54(5): 948-953. |
[4] | 张梅香,史文芝,刘建新,王春键,李燕,王蔚,江滨. MLL-AF6融合基因阳性急性髓系白血病的临床特征及预后[J]. 北京大学学报(医学版), 2021, 53(5): 915-920. |
[5] | 池彦廷,张延平,张秋露,刘翠苓,李斌斌. 唾液腺干燥综合征继发黏膜相关淋巴组织淋巴瘤的临床病理分析[J]. 北京大学学报(医学版), 2021, 53(1): 40-45. |
[6] | 程功,张霞,杨菲,程嘉渝,刘燕鹰. 以发热、关节炎、皮肤色素沉着为主要表现的血管免疫母细胞性T细胞淋巴瘤1例[J]. 北京大学学报(医学版), 2020, 52(6): 1150-1152. |
[7] | 宿骞,彭歆,周传香,俞光岩. 原发性腮腺淋巴瘤的临床病理特点及预后分析[J]. 北京大学学报(医学版), 2019, 51(1): 35-42. |
[8] | 段文冰,宫立众,贾晋松,主鸿鹄,赵晓甦,江倩,赵婷,王婧,秦亚溱,黄晓军,江浩. 伴EVI1高表达的中高危急性髓系白血病临床特点及早期治疗效果[J]. 北京大学学报(医学版), 2017, 49(6): 990-995. |
[9] | 万文丽,王晶,朱明霞,张巍,克晓燕. CHOPE方案结合左旋门冬酰胺酶治疗T细胞淋巴瘤的回顾性分析[J]. 北京大学学报(医学版), 2016, 48(5): 841-845. |
|